Annovis Bio Inc

NYSE ANVS

Data sourced from

and

Daily

Download Data

Annovis Bio Inc Share Price on June 03, 2024: USD 6.81

Annovis Bio Inc Share Price is USD 6.81 on June 03, 2024, a -49.48% change year over year. Share price refers to the current trading price of a single share of a company's stock. It represents the monetary value that investors are willing to pay for ownership in the company. Share prices are determined by the supply and demand dynamics in the stock market and can fluctuate throughout the trading day. Changes in share prices are influenced by various factors, including company performance, industry trends, market conditions, investor sentiment, and economic indicators. Share price is a key indicator used by investors to assess the performance and valuation of a company's stock.

Annovis Bio Inc 52-week high Share Price is USD 19.62 on December 27, 2023, which is 188.11% above the current Share Price.
Annovis Bio Inc 52-week low Share Price is USD 4.82 on May 08, 2024, which is -29.22% below the current Share Price.
Annovis Bio Inc average Share Price for the last 52 weeks is USD 10.66.

NYSE: ANVS

Annovis Bio Inc

CEO	Dr. Maria L. Maccecchini Ph.D.
IPO Date	Feb. 12, 2010
Location	United States
Headquarters	1055 Westlakes Drive, Berwyn, PA, United States, 19312
Employees	6
Sector	Healthcare
Industry	Biotechnology

Description

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405, which is in Phase 2 and Phase 3 efficacy studies, an intravenous drug for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials, an orally administered drug to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Malvern, Pennsylvania.

Key trends